NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ZYDUSLIFE · data 2026-10-31
Zydus Lifesciences Limited
In plain words
Price: at or near its 52-week high.
Delivery: 48.7% of traded shares were kept for delivery over the last 10 sessions, against 51.9% over the last 60.
Latest results: a net profit of ₹64 cr for the quarter ended Mar 2024.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹28,592 cr |
| Net profit (last 12 months) | ₹4,513 cr |
| Sales growth, 3 years (yearly) | 16.6% |
| Profit growth, 3 years (yearly) | 37.0% |
At a glance
Promoters 75.0%, pledged 0.0%, institutions 18.1%.
P/E 27.8, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 19.7%, ROCE 17.8%, operating margin 18.6%: how much profit it earns on the money it uses.
Debt/equity 0.46, Profit growth 37.0% and sales growth 16.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (19.7%).
- Profit grew 37.0% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q4 FY24)
ZYDUSLIFE Q4 FY24 results (consolidated figures, as filed on NSE).
Revenue was ₹5,533.8 crore.
Net profit was ₹63.8 crore.
Operating margin was 29.5%.
EPS was ₹11.69.
ZYDUSLIFE के Q4 FY24 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹5,533.8 करोड़।
शुद्ध मुनाफ़ा: ₹63.8 करोड़।
ऑपरेटिंग मार्जिन: 29.5%।
EPS: ₹11.69।
ZYDUSLIFEના Q4 FY24 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹5,533.8 કરોડ.
ચોખ્ખો નફો: ₹63.8 કરોડ.
ઓપરેટિંગ માર્જિન: 29.5%.
EPS: ₹11.69.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 49.3% over the last 20 sessions vs 48.3% in the 40 before (1.02x); shares delivered per day 0.9x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 11/15: 18 schemes hold it, about ₹2,641 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 49/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 24 Jul 26Dividend Dividend ₹1 (ex-date) -0.5% next session
- 25 Jul 25Dividend Dividend ₹11 (ex-date) +0.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Mar 2024 | ₹5,534 cr | ₹64 cr | — | 29.5% | 11.69 |
| Sept 2023 | ₹4,369 cr | ₹801 cr | +53.2% | 26.2% | 7.91 |
| Dec 2022 | ₹4,362 cr | ₹623 cr | — | 21.9% | 6.15 |
| Sept 2022 | ₹4,135 cr | ₹523 cr | — | 19.7% | 5.15 |
Shareholding trend
| Holder | Jun 2026 | Dec 2024 |
|---|---|---|
| Promoters | 75.01% | 74.98% |
| Foreign institutions (FII) | 6.88% | 7.53% |
| Domestic institutions (DII) | 11.27% | 10.65% |
| Mutual funds | 5.12% | 6.32% |
| Retail investors | 4.71% | 4.69% |
| Number of shareholders | 3,99,251 | 3,65,356 |
Common questions
What was Zydus Lifesciences Limited's latest quarterly profit?
Zydus Lifesciences Limited reported a net profit of ₹64 cr for the quarter ended Mar 2024, on revenue of ₹5,534 cr.
How much do promoters hold in Zydus Lifesciences Limited?
Promoters held 75.01% of Zydus Lifesciences Limited at the end of Jun 2026, with 0.00% of promoter shares pledged.
Is Zydus Lifesciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.46.
What is Zydus Lifesciences Limited's P/E ratio?
About 27.8, based on the last 12 months' earnings and a price of ₹1,245.5 (data 2026-10-31).
What is the 52-week high and low of Zydus Lifesciences Limited?
The 52-week high is ₹1,248.9 and the 52-week low is ₹835.5.
Mutual funds holding Zydus Lifesciences Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 18 schemes holding about ₹2,641 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Parag Parikh Flexi Cap Fund | PPFAS Mutual Fund | 1.54% | ₹2,234 cr |
| NIPPON INDIA ETF NIFTY NEXT 50 JUNIOR BEES | Nippon India Mutual Fund | 1.18% | ₹102 cr |
| Parag Parikh ELSS Tax Saver Fund | PPFAS Mutual Fund | 1.75% | ₹95 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 2.92% | ₹51 cr |
| ADITYA BIRLA SUN LIFE QUANT FUND | Aditya Birla Sun Life Mutual Fund | 2.12% | ₹39 cr |
| SBI Nifty Next 50 ETF | SBI Mutual Fund | 1.18% | ₹34 cr |
| Nippon India Nifty Alpha Low Volatility 30 Index Fund | Nippon India Mutual Fund | 2.79% | ₹33 cr |
| SBI Nifty Next 50 Index Fund | SBI Mutual Fund | 1.19% | ₹28 cr |
| Mirae Asset Nifty Next 50 ETF | Mirae Asset Mutual Fund | 1.18% | ₹17 cr |
| ADITYA BIRLA SUN LIFE NIFTY NEXT 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.18% | ₹3 cr |
| ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF | Aditya Birla Sun Life Mutual Fund | 2.54% | ₹2 cr |
| Mirae Asset Nifty India Manufacturing ETF | Mirae Asset Mutual Fund | 0.69% | ₹2 cr |
| ADITYA BIRLA SUN LIFE NIFTY NEXT 50 ETF | Aditya Birla Sun Life Mutual Fund | 1.18% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 2.14% | ₹0 cr |
| Nippon India Nifty 500 Low Volatility 50 Index Fund | Nippon India Mutual Fund | 0.97% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences Limited | ₹1,245.5 | ₹1,24,089 cr | 27.8 | — | 19.7% | 17.8% | 0.46 | +24.1% |
| Torrent Pharmaceuticals Ltd | ₹4,613.4 | ₹1,76,300 cr | 75.6 | 9.6 | 27.1% | 13.5% | 1.79 | +28.0% |
| Laurus Labs Ltd. | ₹2,405.5 | ₹1,29,243 cr | 97.1 | 21.5 | 18.2% | 20.5% | 0.48 | +149.8% |
| Dr. Reddy's Laboratories Ltd. | ₹1,352 | ₹1,12,643 cr | 40.3 | 2.9 | 12.1% | 12.1% | 0.21 | +13.0% |
| Mankind Pharma Ltd. | ₹2,492.8 | ₹1,02,797 cr | 46 | 5.9 | 12.5% | 12.7% | 0.39 | +1.4% |
| Glenmark Pharmaceuticals Limited | ₹2,298.7 | ₹65,137 cr | 36.1 | — | 14.1% | 29.2% | 0.06 | +24.1% |
Compare ZYDUSLIFE with TORNTPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ZYDUSLIFE in NSE Scanner →